Illumina Inc. is acquiring Conexio Genomics, an Australian firm that specializes in tissue typing used to match patients and donors for bone marrow or cord blood transplants.

Conexio’s system uses a protein found in most cells in the body — human leukocyte antigen or HLA. 

Last year, Illumina introduced its own kit for HLA typing, called the TruSight HLA Sequencing Panel, which is designed to run on the company’s MiSeq benchtop sequencers. Conexio provided the software for that project. As a subsidiary of Illumina, it will continue developing products for more precise organ transplant matching.